Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

4D Molecular Therapeutics

Biotech & Life Sciences · Emeryville, United States · Founded 2013 · IPO 2020 Colt

Design and develop transformative gene therapy products using our proprietary

Valuation
$82M
Market cap · May/2026
Revenue
$85M
Latest reported FY

Investors

21 investors on 4D Molecular Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 1 investor entered at this stage
Cystic Fibrosis Foundation
Series B+ 20 investors entered at this stage
Octagon investments
BVF Partners
Cure Duchenne
Amzak Capital Management
Pappas Capital
Chiesi Ventures
Viking Global Investors
Perceptive Advisors
University of California
Berkeley
ArrowMark Partners
Berkeley Catalyst Fund
Ridgeback Capital
Janus Henderson Investors
Mirae Asset Capital
QUAD Investment Management
Longevity Vision Fund
Pfizer Ventures
Casdin Capital
Pfizer

Global footprint

Where 4D Molecular Therapeutics has talent and traffic

Workforce by country
🇺🇸 United States · Emeryville HQ
Book a demo for the full country breakdown
Web traffic by country
15K monthly visits
across markets
🇺🇸 United States61.3%
🇮🇳 India18.7%
🇬🇧 United Kingdom10.7%
🏳️ Korea6%
🏳️ Republic of1.3%
Top 5 markets shown

Market sentiment

What the market is saying about 4D Molecular Therapeutics

An AI-synthesized read of the highest-engagement posts about 4D Molecular Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See 4D Molecular Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.